providers, the summit is designed to help attendees find solutions to their most pressing clinical trial challenges in 2025 and beyond.
monoamine transporter 2 inhibitor (INGREZZA) in patients treated for chorea. These analyses will be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders Congress hosted by the Parkinson & Movement Disorder Alliance in...
comprehensive metabolic benefits, named by Fierce Pharma as one of the top ten most anticipated drugs globally in 2025. The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate...
Join The Hackett Group and functional and operations leaders to supercharge business change and performance, while leveraging AI for maximum impact. Prepare for Industry Headwinds and Enhance Operational Excellence in Pharma Over the next 5 years,...
(BLA) for this product is expected to be filed with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025. The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has already validated and accepted the marketing...
The Global Pharma Tech Summit 2025 would like to welcome all the pharmaceutical professionals and companies to speak at our prestigious Pharma Summit 2024 slated on June 23 - 24, 2025. The Global Pharma Tech Summit 2025 would like to welcome all...
for Proposals will be reviewed through a two-step process: Letters of Intent will be accepted until midnight on July 29, 2025; if selected, projects will then be chosen to submit full proposals. All applications will be subject to a rigorous review...
head-to-head respiratory trial with biologic medicines and were shared in a late-breaking oral presentation at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. “Patients suffering from chronic rhinosinusitis...
and provide it under GMP conditions for innovators engaged in clinical research." Macrocyclics is an exhibitor at the 2025 SNMMI Annual Meeting, located in New Orleans, LA from June 21 to June 24. Ratio will also have representatives in attendance...
were alive. These results were shared today during an oral presentation at the 30th European Hematology Association (EHA) 2025 Congress. The safety profile of this combination therapy showed cytokine release syndrome (CRS) being low grade and no...
also includes potential future indications. Avanzanite is rapidly scaling its operations, having tripled its revenue in Q1 2025 year-over-year, with two rare disease medicines already on the market. Over the next 12 months, the company will expand...
rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the first quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer commented, "While advancing our core...
Doxycycline for Injection, USP had U.S. sales of approximately $47 million for the twelve months ending in March 2025.1 Indications: Doxycycline for Injection, USP is indicated for the treatment of infections proven or strongly suspected to be...
key global markets. The drug received FDA approval in September 2024 and has been available in the U.S. since March 2025. Otulfi (ustekinumab-aauz) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23, which...
in the U.S. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis was initiated in May 2025. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the...
autonomy for both Spain and the European Union. The Ministry provisionally awarded €53.2 million in funding on May 5, 2025, to support 37 breakthrough projects across 11 autonomous communities. INBRAIN’s project was one of several selected for...
immunoregulatory therapeutics for inflammatory and autoimmune diseases, will present at Digestive Disease Week 2025 first ever head-to-head clinical and translational results from two studies for omilancor, a Phase 3 first-in-class LANCL2 agonist...
comprises capabilities for low- to medium-volume DDC assembly and packaging. Both facilities will be GMP ready in fall 2025. In Europe, PCI recently acquired a packaging and device assembly facility in Dundalk, Ireland, which provides...
and the UK Government, including Innovate UK and the NIHR. The first participant was dosed in the trial on the 15th April 2025 and is expected to be completed in Q3 2025. Stablepharma’s next-generation technology platform StablevaX™ reformulates...
2b study in patients with moderate-to-severely active UC (XENITH-UC), with the expected study start in the second half of 2025. Lead selection for Xencor’s XmAb TL1A x IL23p19 bispecific antibody continues to advance. New in vitro studies show that...
